The proposal would subsidise GLP-1 RAs on the PBS for people who are obese and people with type 2 diabetes requiring intensive insulin therapy, with 8 options, from 1 July 2025. 

• Option 1: Fully subsidise the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes requiring intensive insulin therapy 
• Option 2: Fully subsidise the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes and who are obese requiring intensive insulin therapy. 
• Option 3: Fully subsidise the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes, with or without requiring intensive insulin therapy.
• Option 4: Fully subsidise the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes and who are obese, with or without requiring intensive insulin therapy. 
• Option 5: Partially subsidise (50%) the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes requiring intensive insulin therapy. 
• Option 6: Partially subsidise (50%) the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes and who are obese requiring intensive insulin therapy. 
• Option 7: Partially subsidise (50%) the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes, with or without requiring intensive insulin therapy.
• Option 8: Partially subsidise (50%) the patient PBS co-contribution for all GLP1-RAs available in Australia for people with type 2 diabetes and who are obese, with or without requiring intensive insulin therapy. 

The request also sought distributional analysis of the impact under each option.